

Rolf A Brekken

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8475823/rolf-a-brekken-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

235
papers

15,166
citations

64
h-index

117
g-index

254
ext. papers

17,510
ext. citations

8.5
avg, IF

6.48
L-index

#	Paper	IF	Citations
235	AXL targeting restores PD-1 blockade sensitivity of mutant NSCLC through expansion of TCF1 CD8 T cells.. <i>Cell Reports Medicine</i> , 2022 , 3, 100554	18	4
234	Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages.. <i>Cancer Research</i> , 2022 , 82, 1172-1173	10.1	
233	Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer.. <i>Cancer Cell</i> , 2022 ,	24.3	10
232	Drivers of EMT and Immune Evasion 2022 , 183-194		
231	919 Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment 2021 , 9, A964-A964		
230	VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. <i>JCI Insight</i> , 2021 , 6,	9.9	3
229	High-dimensional immunotyping of tumors grown in obese and non-obese mice. <i>DMM Disease Models and Mechanisms</i> , 2021 , 14,	4.1	2
228	Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	4
227	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. <i>Blood</i> , 2021 , 137, 1839-1842	2.2	2
226	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021 , 19, 1412-1421	6.6	2
225	Perspectives on Hypoxia Signaling in Tumor Stroma. <i>Cancers</i> , 2021 , 13,	6.6	3
224	SPARC is a key mediator of TGF-β-induced renal cancer metastasis. <i>Journal of Cellular Physiology</i> , 2021 , 236, 1926-1938	7	5
223	Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production. <i>Journal of Immunology</i> , 2021 , 207, 436-448	5.3	
222	Neuropathological Effects of Chemotherapeutic Drugs. <i>ACS Chemical Neuroscience</i> , 2021 , 12, 3038-3048	5.7	1
221	DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. <i>JCI Insight</i> , 2021 , 6,	9.9	6
220	MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. <i>Cancer Discovery</i> , 2021 ,	24.4	3
219	Location Matters: Profiling Diffuse Type Gastric Cancer At the Single-Cell Level. <i>Clinical Cancer Research</i> , 2021 , 27, 6284-6286	12.9	

218	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis.. <i>Cancers</i> , 2021 , 13,	6.6	2
217	Pancreatic cancer stroma: an update on therapeutic targeting strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 487-505	24.2	177
216	Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2020 , 319, C233-C243	5.4	12
215	TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy. <i>Cell Communication and Signaling</i> , 2020 , 18, 29	7.5	15
214	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 973-999	8.9	36
213	Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. <i>Gastric Cancer</i> , 2020 , 23, 824-836	7.6	13
212	Procoagulant Activity of Skeletal Muscle Myosin Is Not Caused By Contaminating Phosphatidylserine-Vesicles. <i>Blood</i> , 2020 , 136, 20-21	2.2	
211	Beyond Stiffness: Collagen Signaling in Pancreatic Cancer and Pancreas Regeneration. <i>American Journal of Pathology</i> , 2020 , 190, 1622-1624	5.8	1
210	Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , 2020 , 15, 579-588	5	3
209	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. <i>iScience</i> , 2020 , 23, 101649	6.1	9
208	Wp63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion. <i>Cancer Research</i> , 2020 , 80, 3933-3944	10.1	9
207	Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. <i>Scientific Reports</i> , 2020 , 10, 20662	4.9	1
206	Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. <i>Cancers</i> , 2020 , 12,	6.6	32
205	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2020 , 13, 911-922	3.2	8
204	Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6017-6027	12.9	7
203	Loss of BAP1 Leads to More YAPing in Pancreatic Cancer. <i>Cancer Research</i> , 2020 , 80, 1624-1625	10.1	4
202	APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. <i>Breast Cancer: Targets and Therapy</i> , 2019 , 11, 249-259	3.9	3
201	The effect of flow on blood oxygen level dependent (R) MRI of orthotopic lung tumors. <i>Magnetic Resonance in Medicine</i> , 2019 , 81, 3787-3797	4.4	10

200	Getting a grip on adhesion: Cadherin switching and collagen signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019 , 1866, 118472	4.9	18
199	Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. <i>Molecular Cancer</i> , 2019 , 18, 68	42.1	83
198	Collagen Signaling in Cancer 2019 , 89-108		1
197	2-Amino-2,3-dihydro-1-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 7431-7444	8.3	23
196	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. <i>Frontiers in Oncology</i> , 2019 , 9, 1049	5.3	14
195	Targeting TGF β 2-mutant tumors exposes vulnerabilities to stromal TGF β blockade in pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2019 , 11, e10515	12	28
194	Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. <i>JCI Insight</i> , 2019 , 5,	9.9	16
193	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. <i>JCI Insight</i> , 2019 , 5,	9.9	81
192	Human pancreatic cancer cell exosomes, but not human normal cell exosomes, act as an initiator in cell transformation. <i>ELife</i> , 2019 , 8,	8.9	39
191	Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 25880-25890	11.5	22
190	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , 2019 , 661, 97-106	4.1	3
189	The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. <i>Cancer Research</i> , 2019 , 79, 328-330	10.1	29
188	⌘ Syntrophin Supports Autophagy Initiation and Protects against Cerulein-Induced Acute Pancreatitis. <i>American Journal of Pathology</i> , 2019 , 189, 813-825	5.8	1
187	Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2019 , 17, 348-355	6.6	8
186	Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Immunology</i> , 2019 , 202, 292-299	5.3	21
185	Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. <i>Cell Death and Differentiation</i> , 2019 , 26, 382-393	12.7	31
184	Exploration of Nanoparticle-Mediated Photothermal Effect of TMB-HO Colorimetric System and Its Application in a Visual Quantitative Photothermal Immunoassay. <i>Analytical Chemistry</i> , 2018 , 90, 5930-5937	7.8	124
183	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 7977-7990	8.3	14

182	Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. <i>Neoplasia</i> , 2018 , 20, 826-837	6.4	22
181	Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma. <i>Molecular Cancer Research</i> , 2018 , 16, 1590-1600	6.6	23
180	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018 , 78, 246-255	10.1	86
179	Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. <i>Journal of Cell Communication and Signaling</i> , 2018 , 12, 83-90	5.2	24
178	Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. <i>JCI Insight</i> , 2018 , 3,	9.9	45
177	Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor- β receptor type I inhibitor. <i>Oncotarget</i> , 2018 , 9, 6659-6677	3.3	75
176	Does Axl have potential as a therapeutic target in pancreatic cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 955-966	6.4	13
175	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. <i>ImmunoTargets and Therapy</i> , 2018 , 7, 1-14	9	22
174	Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction. <i>Molecular Metabolism</i> , 2018 , 16, 139-149	8.8	10
173	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nature Communications</i> , 2017 , 8, 14098	17.4	54
172	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 662-670	6.1	14
171	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017 , 8, 327-332	4.3	22
170	Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. <i>BMC Cancer</i> , 2017 , 17, 87	4.8	33
169	A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. <i>Oncogene</i> , 2017 , 36, 5122-5133	9.2	61
168	Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies. <i>British Journal of Cancer</i> , 2017 , 117, 545-552	8.7	67
167	From top to bottom: midkine and pleiotrophin as emerging players in immune regulation. <i>Journal of Leukocyte Biology</i> , 2017 , 102, 277-286	6.5	22
166	Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and α AR-Dependent Neo-Angiogenic Switch. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1442-1454	6.3	39
165	Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. <i>Nature Cell Biology</i> , 2017 , 19, 1226-1236	23.4	29

164	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2473-2485	6.1	53
163	The Extracellular Matrix of Tumors: A Focus on Fibronectin and Fibulin-5. <i>Biology of Extracellular Matrix</i> , 2017 , 1-15	0.6	
162	Extracellular Matrix Induction of Intracellular Reactive Oxygen Species. <i>Antioxidants and Redox Signaling</i> , 2017 , 27, 774-784	8.4	14
161	Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend <i>C. elegans</i> lifespan. <i>Nature Communications</i> , 2017 , 8, 2270	17.4	79
160	Drivers of EMT and Immune Evasion 2017 , 221-239		1
159	A Transistor-like pH Nanoprobe for Tumour Detection and Image-guided Surgery. <i>Nature Biomedical Engineering</i> , 2016 , 1,	19	107
158	Hypoxia and Transforming Growth Factor β Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer. <i>Journal of Biological Chemistry</i> , 2016 , 291, 22244-22252	5.4	27
157	The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. <i>Science Translational Medicine</i> , 2016 , 8, 365ra159	17.5	34
156	Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. <i>Cell Death and Differentiation</i> , 2016 , 23, 962-78	12.7	328
155	P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. <i>Cell Reports</i> , 2016 , 14, 2193-2208	10.6	30
154	Matrix control of pancreatic cancer: New insights into fibronectin signaling. <i>Cancer Letters</i> , 2016 , 381, 252-8	9.9	64
153	Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. <i>Oncotarget</i> , 2016 , 7, 51569-51580	3.3	16
152	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. <i>Oncotarget</i> , 2016 , 7, 30678-90	3.3	27
151	The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. <i>Current Drug Targets</i> , 2016 , 17, 1747-1754	3	6
150	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016 , 11, e0158757	3.7	19
149	Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy. <i>Radiation Research</i> , 2016 , 185, 616-22	3.1	7
148	Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 5911-6	8.3	32
147	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1357-1362	8.9	25

146	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. <i>Cancer Immunology Research</i> , 2016 , 4, 531-40	12.5	16
145	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. <i>Annals of Surgical Oncology</i> , 2016 , 23, 583-591	3.1	13
144	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. <i>Cancer Research</i> , 2015 , 75, 3699-705	10.1	88
143	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. <i>Nature Chemical Biology</i> , 2015 , 11, 401-8	11.7	38
142	Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. <i>ACS Chemical Biology</i> , 2015 , 10, 2891-9	4.9	23
141	A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1201-11	4.1	11
140	NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by Elapachone. <i>Cell Death and Disease</i> , 2015 , 6, e1599	9.8	60
139	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. <i>Cancer Research</i> , 2015 , 75, 5058-69	10.1	28
138	Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo 2015 , 56, 7137-45		8
137	Stromal TGFBR2 signaling: a gateway to progression for pancreatic cancer. <i>Molecular and Cellular Oncology</i> , 2015 , 2, e975606	1.2	5
136	CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. <i>Cancer Letters</i> , 2015 , 359, 335-43	9.9	61
135	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. <i>Cancer Letters</i> , 2015 , 358, 59-66	9.9	37
134	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4063-76	15.9	47
133	Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 5, 493-503	2.2	12
132	Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. <i>Cancer Research</i> , 2014 , 74, 1032-44	10.1	62
131	Vascular channels formed by subpopulations of PECAM1+ melanoma cells. <i>Nature Communications</i> , 2014 , 5, 5200	17.4	48
130	Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 15999-6004	11.5	37
129	Faulty ECM signaling facilitates autoimmune lymphomagenesis. <i>Cancer Discovery</i> , 2014 , 4, 25-6	24.4	4

128	Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. <i>Gastroenterology</i> , 2014 , 146, 1339-50.e1	13.3	160
127	Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. <i>Journal of Clinical Investigation</i> , 2014 , 124, 824-34	15.9	58
126	Role of SPARC in bone remodeling and cancer-related bone metastasis. <i>Journal of Cellular Biochemistry</i> , 2014 , 115, 17-26	4.7	39
125	Neutralizing murine TGF β 2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. <i>Cancer Research</i> , 2014 , 74, 4996-5007	10.1	44
124	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. <i>Molecular Cancer</i> , 2014 , 13, 237	42.1	49
123	Recruitment and retention: factors that affect pericyte migration. <i>Cellular and Molecular Life Sciences</i> , 2014 , 71, 299-309	10.3	50
122	Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.. <i>Clinical Cancer Research</i> , 2014 , 20, B30-B30	12.9	3
121	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. <i>Oncotarget</i> , 2014 , 5, 9811-22	3.3	32
120	Hypoxia Studies with Pimonidazole. <i>Bio-protocol</i> , 2014 , 4,	0.9	47
119	27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. <i>Cell Reports</i> , 2013 , 5, 637-45	10.6	230
118	Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. <i>Cell</i> , 2013 , 155, 552-66	56.2	129
117	VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. <i>Molecular Therapy</i> , 2013 , 21, 1014-23	11.7	27
116	A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. <i>Nature Communications</i> , 2013 , 4, 2035	17.4	197
115	Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model. <i>Molecular Pharmaceutics</i> , 2013 , 10, 307-18	5.6	25
114	RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. <i>Cancer Discovery</i> , 2013 , 3, 444-57	24.4	84
113	PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1190-201	6.1	49
112	BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 992-1001	6.1	80
111	Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulinitis and restoring islet function. <i>Diabetes</i> , 2013 , 62, 2870-8	0.9	20

110	Loss of SPARC in bladder cancer enhances carcinogenesis and progression. <i>Journal of Clinical Investigation</i> , 2013 , 123, 751-66	15.9	54
109	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 1732-40	15.9	142
108	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3183-3183	15.9	7
107	Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. <i>PLoS ONE</i> , 2013 , 8, e63402	3.7	65
106	Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature. <i>PLoS ONE</i> , 2013 , 8, e74686	3.7	44
105	Mouse Models of Pancreatic Cancer 2013 , 57-91		1
104	Accumulation of pro-cancer cytokines in the plasma fraction of stored packed red cells. <i>Journal of Gastrointestinal Surgery</i> , 2012 , 16, 460-8	3.3	29
103	Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 5031-42	12.9	48
102	Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF β activation. <i>PLoS ONE</i> , 2012 , 7, e31384	3.7	56
101	Stromal platelet-derived growth factor receptor α (PDGFR α) provides a therapeutic target independent of tumor cell PDGFR β expression in lung cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2473-82	6.1	31
100	Lack of "immunological fitness" during fasting in metabolically challenged animals. <i>Journal of Lipid Research</i> , 2012 , 53, 1254-67	6.3	30
99	Dichotomous effects of VEGF-A on adipose tissue dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5874-9	11.5	273
98	Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. <i>Carcinogenesis</i> , 2012 , 33, 1639-46	4.6	18
97	TGF- β and α 5 β integrin act in a common pathway to suppress pancreatic cancer progression. <i>Cancer Research</i> , 2012 , 72, 4840-5	10.1	69
96	Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?. <i>Cancer Discovery</i> , 2012 , 2, 211-324.4		3
95	Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 230-230	2.2	
94	Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 234-234	2.2	
93	Rgs16 is a pancreatic reporter of chronic hyperglycemia in diabetes. <i>FASEB Journal</i> , 2012 , 26, 759.6	0.9	

92	Ligand induced activation of VEGFR during angiogenesis. <i>FASEB Journal</i> , 2012 , 26, 971.2	0.9	
91	Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13563-e13563	2.2	
90	TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. <i>Molecular Cell</i> , 2011 , 41, 458-70	17.6	158
89	Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium. <i>PLoS ONE</i> , 2011 , 6, e28947	3.7	61
88	Update on vascular disrupting agents for cancer therapy. <i>Therapy: Open Access in Clinical Medicine</i> , 2011 , 8, 403-413		1
87	The regulatory function of SPARC in vascular biology. <i>Cellular and Molecular Life Sciences</i> , 2011 , 68, 3165-33	7.3	67
86	SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-independent manner. <i>Cancer Research</i> , 2011 , 71, 7640-8	10.1	47
85	Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. <i>Cancer Biology and Therapy</i> , 2011 , 12, 617-28	4.6	25
84	Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of Elapachone for pancreatic cancer therapy. <i>Clinical Cancer Research</i> , 2011 , 17, 275-85	12.9	92
83	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF- β activity. <i>Journal of Cell Biology</i> , 2011 , 193, 1305-19	7.3	55
82	SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/ α 1 integrin axis. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 2438-47	4.3	44
81	SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 301, H841-7	5.2	51
80	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF- β 1 activity. <i>Journal of Experimental Medicine</i> , 2011 , 208, i22-i22	16.6	
79	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. <i>Anticancer Research</i> , 2011 , 31, 843-7	2.3	5
78	VEGF and pleiotrophin modulate the immune profile of breast cancer. <i>Cancers</i> , 2010 , 2, 970-88	6.6	17
77	r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. <i>PLoS ONE</i> , 2010 , 5, e12031	3.7	33
76	Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. <i>Experimental Biology and Medicine</i> , 2010 , 235, 3-9	3.7	35
75	Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. <i>Experimental Biology and Medicine</i> , 2010 , 235, 263-70	3.7	35

74	Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood. <i>Circulation Research</i> , 2010 , 107, 1460-9	15.7	23
73	Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2010 , 3, 57-72	4.1	86
72	Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS. <i>DMM Disease Models and Mechanisms</i> , 2010 , 3, 333-42	4.1	51
71	Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 3170-80	4.3	21
70	Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. <i>Cancer Research</i> , 2010 , 70, 2852-61	10.1	86
69	Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. <i>DMM Disease Models and Mechanisms</i> , 2010 , 3, 567-80	4.1	30
68	MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. <i>Journal of the American Chemical Society</i> , 2010 , 132, 12829-31	16.4	44
67	The VEGF family in cancer and antibody-based strategies for their inhibition. <i>MAbs</i> , 2010 , 2, 165-75	6.6	119
66	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. <i>BMC Cancer</i> , 2010 , 10, 397	4.8	29
65	Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. <i>Cancer</i> , 2010 , 116, 3862-74	6.4	20
64	Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2319-30	15.9	194
63	The Function of SPARC in Tumor Cell Biology: SPARC as a Modulator of Cell-Extracellular Matrix Interaction 2010 , 171-189		
62	Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. <i>PLoS ONE</i> , 2009 , 4, e7669	3.7	138
61	Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. <i>Molecular and Cellular Biology</i> , 2009 , 29, 4467-83	4.8	578
60	Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1761-71	6.1	127
59	K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. <i>Molecular Cancer Research</i> , 2009 , 7, 799-808	6.6	61
58	Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. <i>Journal of Cell Communication and Signaling</i> , 2009 , 3, 337-47	5.2	104
57	SPARC: a matricellular regulator of tumorigenesis. <i>Journal of Cell Communication and Signaling</i> , 2009 , 3, 255-73	5.2	121

56	Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. <i>Nature Medicine</i> , 2009 , 15, 1023-30	50.5	286
55	Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 200, 180.e1-7	6.4	15
54	The acellular fraction of stored platelets promotes tumor cell invasion. <i>Journal of Surgical Research</i> , 2009 , 153, 132-7	2.5	21
53	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. <i>PLoS ONE</i> , 2009 , 4, e7464	3.7	172
52	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. <i>BMC Cancer</i> , 2008 , 8, 352	4.8	51
51	A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. <i>Journal of the American Chemical Society</i> , 2008 , 130, 5744-52	16.4	196
50	Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. <i>Cancer Research</i> , 2008 , 68, 4340-6	10.1	154
49	Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. <i>Experimental Biology and Medicine</i> , 2008 , 233, 860-73	3.7	54
48	Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. <i>Cancer Research</i> , 2008 , 68, 9050-9	10.1	146
47	Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. <i>Cancer Research</i> , 2008 , 68, 8295-303	10.1	59
46	A peptoid antagonist of VEGF receptor 2 recognizes a hotspot in the extracellular domain distinct from the hormone-binding site. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 6338-43	3.4	26
45	The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 5892-4	2.9	30
44	The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. <i>International Journal of Cancer</i> , 2007 , 120, 753-60	7.5	39
43	Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. <i>International Journal of Cancer</i> , 2007 , 121, 2181-91	7.5	80
42	Progesterin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. <i>Cancer Research</i> , 2007 , 67, 9929-36	10.1	67
41	Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. <i>Clinical Cancer Research</i> , 2007 , 13, 323-30	12.9	228
40	Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. <i>Cancer Research</i> , 2007 , 67, 9435-42	10.1	55
39	Angiogenic role of LYVE-1-positive macrophages in adipose tissue. <i>Circulation Research</i> , 2007 , 100, e47-57	15.7	199

38	Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. <i>International Journal of Cancer</i> , 2006 , 118, 2639-43	7.5	67
37	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. <i>Endocrine-Related Cancer</i> , 2006 , 13, 905-19	5.7	106
36	Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer 2006 , 179-194		1
35	Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. <i>Neurosurgery</i> , 2006 , 59, 374-82; discussion 374-82	3.2	51
34	Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. <i>Annals of Surgical Oncology</i> , 2006 , 13, 1145-55	3.1	27
33	Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. <i>Journal of Clinical Investigation</i> , 2006 , 116, 422-9	15.9	69
32	Targeting vascular endothelium with avidin microbubbles. <i>Ultrasound in Medicine and Biology</i> , 2005 , 31, 1279-83	3.5	78
31	Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. <i>Journal of the American College of Surgeons</i> , 2005 , 200, 371-7	4.4	70
30	Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. <i>Molecular Cancer Research</i> , 2005 , 3, 413-23	6.6	160
29	SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. <i>Journal of Histochemistry and Cytochemistry</i> , 2005 , 53, 571-81	3.4	28
28	Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. <i>Journal of Histochemistry and Cytochemistry</i> , 2004 , 52, 723-33	3.4	34
27	Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. <i>Journal of Histochemistry and Cytochemistry</i> , 2004 , 52, 735-48	3.4	51
26	Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. <i>Circulation Research</i> , 2004 , 94, 984-92	15.7	102
25	Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 6993-7000	12.9	69
24	SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. <i>Journal of Cellular Biochemistry</i> , 2004 , 91, 915-25	4.7	84
23	SPARC-like 1 regulates the terminal phase of radial glia-guided migration in the cerebral cortex. <i>Neuron</i> , 2004 , 41, 57-69	13.9	93
22	Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. <i>Molecular Cancer Research</i> , 2004 , 2, 215-24	6.6	68
21	Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis. <i>Molecular Cancer Research</i> , 2004 , 2, 215-224	6.6	103

20	Role of VEGF-A in vascularization of pancreatic islets. <i>Current Biology</i> , 2003 , 13, 1070-4	6.3	320
19	Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2003 , 90, 492-501	4.7	13
18	Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. <i>American Journal of Pathology</i> , 2003 , 162, 627-35	5.8	57
17	The matricellular protein SPARC is expressed in human trabecular meshwork. <i>Experimental Eye Research</i> , 2003 , 77, 601-7	3.7	51
16	Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. <i>Journal of Clinical Investigation</i> , 2003 , 111, 487-95	15.9	158
15	Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. <i>Cancer Research</i> , 2003 , 63, 5376-80	10.1	135
14	Strategies for vascular targeting in tumors. <i>International Journal of Cancer</i> , 2002 , 100, 123-30	7.5	48
13	Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. <i>Oncogene</i> , 2002 , 21, 7011-26	9.2	289
12	Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. <i>Wound Repair and Regeneration</i> , 2001 , 9, 522-30	3.6	56
11	The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. <i>Cancer</i> , 2001 , 92, 2569-77	6.4	67
10	SPARC, a matricellular protein: at the crossroads of cell-matrix communication. <i>Matrix Biology</i> , 2001 , 19, 816-27	11.4	417
9	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. <i>Nature Cell Biology</i> , 2000 , 2, 737-44	23.4	2191
8	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000 , 18, 313-9	4.7	6
7	Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. <i>Journal of Histochemistry and Cytochemistry</i> , 2000 , 48, 545-56	3.4	103
6	SPARC, a matricellular protein: at the crossroads of cell-matrix. <i>Matrix Biology</i> , 2000 , 19, 569-80	11.4	249
5	Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 252, 643-8	3.4	28
4	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution		5
3	Contributions of the Extracellular Matrix to Tumorigenesis		35-52

2	PRSS2 stimulates tumor growth by remodeling the TME via repression of Tsp1	1
1	Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer	3